<DOC>
	<DOCNO>NCT00277693</DOCNO>
	<brief_summary>The purpose present study determine spironolactone safe effective treatment cardiovascular complication hemodialysis patient .</brief_summary>
	<brief_title>Cardiovascular Protective Effect Spironolactone Hemodialysis</brief_title>
	<detailed_description>Cardiovascular complication common dialysis patient comprise 50 % deaths end-stage renal disease population . Hypertension leave ventricle hypertrophy occur 70 % patient undergoing long-term hemodialysis therapy , contribute mortality morbidity.Recent clinical trial chronic heart failure post miocardial infarct heart failure patient demonstrate beneficial effect mineralocorticoid receptor blocker spironolactone , adittion standard therapy ( RALES AND EPHESUS study ) . The aim present study evaluate spironolactone treatment hemodialysis patient .</detailed_description>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>chronic hemodialysys ( &gt; 3 month ) anuria ( diuresis &lt; 200 mL/day ) Liver failure Insulin dependent diabetes Treatment adrenergic beta blocker agonists Treatment convertingenzime blocker angiotensin receptor antagonists Cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>aldosterone</keyword>
	<keyword>heart failure</keyword>
	<keyword>spironolactone</keyword>
</DOC>